Add to a list

Inactive Instrument

Immune Therapeutics, Inc. Stock Other OTC

IMUN

US45252A1079

Biotechnology & Medical Research

OTC Markets Traded

Valuation: Immune Therapeutics, Inc.

Market Cap	1.34M 1.2M 1.12M 1.02M 1.91M 127M 1.92M 13.47M 5.26M 66.09M 5.02M 4.92M 213M	P/E 2022	-6x	P/E 2023	-3.65x
Enterprise Value	2.49M 2.24M 2.09M 1.9M 3.56M 237M 3.58M 25.1M 9.8M 123M 9.36M 9.15M 396M	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	42.24%	Yield 2022 *	-	Yield 2023	-

* Estimated data More valuation ratios

Latest news: Immune Therapeutics, Inc.

03-27	Callan Jmb Inc. Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2B/3 Advancement in A Collaboration Led by Difgen Pharmaceuticals, Aveva Drug Delivery Systems, Biostax Corp and Sgp Holdings	CI
03-25	DifGen Pharmaceuticals and Aveva Drug Delivery Systems Form Strategic Platform Collaboration with Biostax Corp D/B/A Attune Biotech, SGP Holdings, and Callan JMB	CI
01-15	Callan JMB Signs Manufacturing Oversight, Federal Deployment, and Commercialization Agreement of Multi-Asset Therapeutic Pipeline with Attune	CI
12-22	Biostax Corp. announced that it expects to receive $7.453728 million in funding	CI
11/04/25	Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
19/08/24	Biostax Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
05/07/24	Biostax Corp. Auditor Raises 'Going Concern' Doubt	CI
20/05/24	Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/04/24	Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/11/23	Biostax Corp. Appoints Craig Suro as a Director	CI
14/11/23	Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
02/11/23	Biostax Corp. Appoints Mary Clay Caperton to its Board of Directors	CI
05/10/23	Immune Therapeutics, Inc. will Change its Name to Biostax Corp	CI

More news

Press Releases: Immune Therapeutics, Inc.

21/02/25	Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration	AQ
30/11/23	Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception	AQ
15/11/23	Biostax Announces a Director Appointment of Influential Business Leader Craig Suro	AQ
02/11/23	Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors	AQ
24/10/23	Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment	AQ

More press releases

Managers and Directors: Immune Therapeutics, Inc.

Manager	Title	Age	Since
Kelly Wilson CEO	Chief Executive Officer	55	03/11/2022
Noreen Griffin CEO	Chief Executive Officer	73	01/03/2012
Glen Farmer DFI	Director of Finance/CFO	57	02/08/2022

Director	Title	Age	Since
Robert Wilson BRD	Director/Board Member	53	31/05/2022
Mary Caperton BRD	Director/Board Member	64	24/10/2023
Roger Suro BRD	Director/Board Member	52	08/11/2023

More insiders

Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNE THERAPEUTICS, INC.	+2.27%	-5.39%	-	-	21.65K
WUXI APPTEC CO., LTD.	-2.01%	-7.86%	+54.60%	+70.97%	70.44B
ARGENX SE	+3.84%	-11.02%	+8.59%	+58.77%	50.31B
LONZA GROUP AG	+3.35%	+1.42%	+11.85%	+37.39%	47.51B
IQVIA HOLDINGS INC.	+0.55%	+1.69%	+28.18%	+31.90%	42.91B
REVOLUTION MEDICINES, INC.	+2.82%	-3.83%	+306.67%	+466.15%	40.39B
BEONE MEDICINES AG	+0.64%	-3.52%	+9.44%	+101.92%	39.69B
CELLTRION, INC.	+0.06%	-1.43%	+10.47%	+43.27%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	-2.95%	-14.09%	+37.94%	+1.30%	26.8B
BIONTECH SE	-0.44%	-6.89%	-13.57%	-8.54%	22.36B
Average	+0.79%	-5.58%	+50.46%	+89.24%	41.22B
Weighted average by Cap.	+0.74%	-5.44%	+53.49%	+94.72%

	2022	2023
Net sales	-	-
Net income	-3.54M -3.18M -2.97M -2.69M -5.05M -337M -5.08M -35.61M -13.9M -175M -13.28M -12.99M -562M	-1.65M -1.48M -1.38M -1.26M -2.36M -157M -2.37M -16.62M -6.49M -81.52M -6.2M -6.06M -262M
Net Debt	546K 491K 458K 415K 780K 51.96M 784K 5.5M 2.15M 26.97M 2.05M 2.01M 86.73M	1.15M 1.04M 968K 878K 1.65M 110M 1.66M 11.62M 4.54M 57.01M 4.33M 4.24M 183M

Immune Therapeutics, Inc. Stock Other OTC

Stocks

IMUN

US45252A1079

Biotechnology & Medical Research

Valuation: Immune Therapeutics, Inc.

Latest news: Immune Therapeutics, Inc.

Press Releases: Immune Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Immune Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile